New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Affimed N.V.
AFMD
Shape
US Flag

NASDAQ

Unprofitable

EPS improving

Unprofitable

EPS improving

51M

Biotechnology

Next Earning date - 12 Nov 2024

51M

Biotechnology

Next Earning date - 12 Nov 2024

3.33USD
Shape0.01 ( 0.15%)
favorite-chart

Relative Strenght

9
favorite-chart

Volume Buzz

2%
favorite-chart

Earning Acce

Yes
favorite-chart

Dist 52w H.

63%

Quote Panel

Shape
Updated October 26, 2024
1W -2.06 % 1M -0.89 % 3M -36.08 % 1Y 5.05 %

Key Metrics

Shape
  • Market Cap

    50.63M


  • Shares Outstanding

    15.23M


  • Share in Float

    13.02M


  • Dividende

    0


  • Earning Date

    12 Nov 2024


  • Price Target

    3.325


  • Average Volume

    86257


  • Beta

    2.1


  • Range

    2.24-8.95


  • Industry

    Biotechnology


  • Website

    https://www.affimed.com


  • Sector

    Healthcare


Fundamentals

Shape

N/A

P/E Ratio

17.46x

P/S Ratio

1.64x

P/B Ratio

0.5

Debt/Equity

-2950.3%

Net Margin

$-5.7

EPS

How AFMD compares to sector?

P/E Ratio

Relative Strength

Shape

AFMD

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

$5M

Shape3001%

2025-Revenue

$2.36

Shape-133%

2025-EPS

$5M

Shape68%

2025-EBITDA

Analyst rating

No Data Available

Last analyst upgrade/downgrade

H.C. Wainwright

initialise

Previous: Not converted

2022-12-12

Now: Buy

Stifel Nicolaus

downgrade

Previous: Not converted

2022-10-11

Now: Positive

Piper Sandler

initialise

Previous: Not converted

2022-03-31

Now: Overweight

Cantor Fitzgerald

initialise

Previous: Not converted

2022-02-23

Now: Overweight

Earnings GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

N/A

-1.10
vs -1.70

Q4.22

arrow
arrow

N/A

-2.20
vs -2.20

Q1.23

arrow
arrow

N/A

-2.30
vs -1.60

Q2.23

arrow
arrow

N/A

-2.20
vs -1.40

Q3.23

arrow
arrow

N/A

-1.70
vs -1.10

Q4.23

arrow
arrow

N/A

-2.20
vs -2.20

Q1.24

arrow
arrow

N/A

-1.38
vs -2.30

Q2.24

arrow
arrow

N/A

-1.09
vs -2.20

Q3.24

arrow
arrow

N/A

-0.92
vs -1.70

Q4.24

arrow
arrow

N/A

-0.68
vs -2.20

Sales GrowthShape

status-upYoY

Current

Estimates

Q3.22

arrow
arrow

+72%

14.9M  vs 8.7M

Q4.22

arrow
arrow

+8%

11.2M  vs 10.3M

Q1.23

arrow
arrow

-44%

4.5M  vs 8M

Q2.23

arrow
arrow

-81%

1.4M  vs 7.3M

Q3.23

arrow
arrow

-87%

2M  vs 14.9M

Q4.23

arrow
arrow

-96%

413K  vs 11.2M

Q1.24

arrow
arrow

-97%

155K  vs 4.5M

Q2.24

arrow
arrow

-89%

154K  vs 1.4M

Q3.24

arrow
arrow

-15%

1.7M  vs 2M

Q4.24

arrow
arrow

+293%

1.6M  vs 413K

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-8%

-0.08
vs -0.09

Q4.22

arrow
arrow

-24%

-0.24
vs -0.08

Q1.23

arrow
arrow

-26%

-0.26
vs -0.24

Q2.23

arrow
arrow

-30%

-0.30
vs -0.26

Q3.23

arrow
arrow

-32%

-0.32
vs -0.30

Q4.23

arrow
arrow

-35%

-0.35
vs -0.32

Q1.24

arrow
arrow

-47%

-0.47
vs -0.35

Q2.24

arrow
arrow

-54%

-0.54
vs -0.47

Institutionnal OwnershipShape

status-upQoQ

Q2.22

arrow
arrow

132

132
vs 118

12%

Q3.22

arrow
arrow

129

129
vs 132

-2%

Q4.22

arrow
arrow

120

120
vs 129

-7%

Q1.23

arrow
arrow

93

93
vs 120

-22%

Q2.23

arrow
arrow

79

79
vs 93

-15%

Q3.23

arrow
arrow

59

59
vs 79

-25%

Q4.23

arrow
arrow

66

66
vs 59

12%

Q1.24

arrow
arrow

1

1
vs 66

-98%

Earnings Growth

Latest News